TENX TENAX THERAPEUTICS, INC.

CIK 0000034956 50 ready 8-Ks latest July 2, 2026, 8:00 AM ET RSS · JSON

Activity: ELEVATED 3 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing July 2, 2026, 8:00 AM ET

Top materiality 0.85

Event mix other_material ×25 · regulatory ×10 · earnings ×9

Sentiment 21 pos · 5 neg · 24 neu

Latest earnings ▲ beat 2026-Q1

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for TENX

Highest-materiality recent filing

Tenax Therapeutics Raises $100M in Oversubscribed Private Placement Led by BVF Partners

August 6, 2024, 7:59 PM ET other material materiality 0.85 positive item 1.01 item 3.02 item 8.01 item 9.01

Gross proceeds ~$100M from 1.45M shares, 31.9M pre-funded warrants, and 16.7M warrants at $3.00/share (warrant strike $4.50).
Private placement led by BVF Partners LP; new investors include Venrock, Vivo Capital, Janus Henderson, Vestal Point, Velan Capital, ADAR1, Stonepine, Sphera Biotech.

Read filing →

July 2, 2026, 8:00 AM ET other material materiality 0.65 neutral item 8.01 item 9.01

Tenax Therapeutics to present Phase 3 LEVEL trial results at ESC Congress 2026; topline data expected in August

Phase 3 LEVEL trial results to be presented in Late-Breaking Clinical Science session at ESC Congress 2026 (Aug 28-31, Munich).
June 30, 2026, 4:30 PM ET other material materiality 0.50 neutral item 1.01 item 9.01

Tenax Therapeutics enters supply agreement with Orion; extends regulatory approval deadline to 2035

Supply Agreement with Orion for oral levosimendan; 5-year initial term, auto-renewing 3-year periods.
June 29, 2026, 4:40 PM ET other material materiality 0.45 neutral item 5.02 item 8.01 item 9.01

Tenax adopts CIC/Severance Plans; amends CEO Giordano's agreement

Board adopted double-trigger Change in Control Plan and Severance Plan on June 26, 2026.
June 4, 2026, 4:10 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×2

Tenax Therapeutics reports results of 2026 annual shareholder meeting

Stockholders elected seven directors: June Almenoff (17.36M for), Michael Davidson (15.76M), Declan Doogan, Christopher T. Giordano, Robyn M. Hunter, Gerald T. Proehl, Stuart Rich.
May 12, 2026, 8:00 AM ET earnings materiality 0.45 neutral item 2.02 item 9.01 ◈ Earnings Releases

Tenax Q1 net loss $15.7M; cash $118.8M; Phase 3 topline data expected Q3 2026

Net loss of $15.7M for Q1 2026 vs $10.4M in Q1 2025; R&D expense rose to $11.5M from $5.7M.
April 22, 2026, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 item 8.01 item 9.01

Tenax Therapeutics appoints Thomas R. Staab, II as CFO effective May 11, 2026

Staab, a 25-year healthcare finance veteran, most recently CFO of LENSAR (LNSR) until May 2026.
March 10, 2026, 7:59 PM ET other material materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Tenax Therapeutics reports Q4/FY2025 loss; LEVEL study fully enrolled, topline Q3 2026

Achieved 230-patient randomization target in Phase 3 LEVEL study; topline data expected Q3 2026.
January 9, 2026, 6:59 PM ET leadership materiality 0.20 neutral item 5.02 item 9.01

Tenax CMO Dr. Stuart Rich moves to 4-day work week; salary prorated 80%

Effective Jan 1, 2026, Dr. Rich will average 4 days per week as CMO.
December 17, 2025, 6:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Tenax Therapeutics confirms LEVEL Phase 3 trial enrollment on track; initiates global LEVEL-2 study

Blinded Sample Size Re-estimation (BSSR) shows LEVEL is powered >90% to detect 25m change in 6MWD primary endpoint.
November 12, 2025, 6:59 PM ET earnings materiality 0.50 neutral item 2.02 item 9.01

Tenax Therapeutics Q3 net loss $15.8M; Phase 3 LEVEL enrollment on track

Net loss of $15.8M for Q3 2025 vs $4.0M in Q3 2024; R&D expenses $10.3M (up from $3.1M).
September 16, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Tenax Therapeutics receives EPO intention to grant patent for levosimendan in PH-HFpEF through 2040

EPO intends to grant patent covering TNX-103 (oral levosimendan) and other formulations for PH-HFpEF.
September 9, 2025, 7:59 PM ET other material materiality 0.80 positive item 1.01 item 9.01

Tenax Therapeutics expands levosimendan license to exclusive worldwide oral rights; gains manufacturing rights

Amendment with Orion grants Tenax exclusive worldwide rights to develop, commercialize, and manufacture oral levosimendan products.
August 13, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Tenax Therapeutics reports Q2 net loss of $10.9M; Phase 3 LEVEL study enrollment on track for H1 2026

Net loss of $10.9M in Q2 2025 vs $3.6M in Q2 2024; R&D spend $6.1M, G&A $5.7M.
June 17, 2025, 7:59 PM ET other material materiality 0.20 neutral item 5.03 item 5.07 item 9.01 ◈ Governance Changes

Tenax Therapeutics shareholders approve officer exculpation, reject meeting-vote mandate

Shareholders approved officer exculpation amendment (2,458,203 for, 10,244 against); effective upon filing.
May 14, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Tenax Therapeutics Q1 net loss $10.4M; Phase 3 LEVEL enrollment on track for year-end 2025

Net loss $10.4M in Q1 2025 vs $3.8M in Q1 2024; company is a development-stage biotech with no revenue.
March 25, 2025, 7:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01

Tenax Therapeutics reports FY2024 net loss of $17.6M; $94.9M cash; raised $125M for TNX-103 Phase 3 trials

Net loss for FY2024 was $17.6M vs $7.7M in 2023; Q4 net loss $6.3M vs $3.2M.
March 6, 2025, 6:59 PM ET other material materiality 0.75 positive item 1.01 item 3.02 item 8.01 item 9.01

Tenax raises $25M, expands Phase 3 LEVEL study to 230 patients, adds LEVEL-2 trial

Private placement with RTW Investments grossed ~$25M; issued 378K shares + pre-funded warrants for 3.76M shares at $6.04/$6.03.
December 4, 2024, 6:59 PM ET leadership materiality 0.55 neutral item 5.02 item 9.01

Tenax Therapeutics appoints Thomas A. McGauley as Interim CFO, effective Dec 2, 2024

Thomas A. McGauley appointed Interim CFO and principal financial/accounting officer, replacing Lawrence R. Hoffman.
November 13, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Tenax Therapeutics Q3 net loss $4.0M; raised $100M private placement

Net loss of $4.0M for Q3 2024 vs $2.0M in Q3 2023; R&D expenses $3.1M (up from $1.1M).
October 30, 2024, 7:59 PM ET other material materiality 0.65 negative item 5.02 item 5.07 item 9.01

Stockholders approve 7.9M share increase in 2022 Stock Incentive Plan

Approved Amendment No. 2 to 2022 Stock Incentive Plan, increasing authorized shares to 8,336,600 (7,935,912 new shares).
August 13, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Tenax Therapeutics reports Q2 net loss of $3.6M, cash $9.4M; raised $100M

Net loss of $3.6M ($1.83/sh) vs loss of $1.1M ($4.00/sh) in Q2 2023.
August 12, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 9.01

Tenax Therapeutics closes $100M private placement to fund Phase 3 levosimendan program

Gross proceeds of ~$100M from oversubscribed private placement led by BVF Partners.
August 6, 2024, 7:59 PM ET other material materiality 0.85 positive item 1.01 item 3.02 item 8.01 item 9.01

Tenax Therapeutics Raises $100M in Oversubscribed Private Placement Led by BVF Partners

Gross proceeds ~$100M from 1.45M shares, 31.9M pre-funded warrants, and 16.7M warrants at $3.00/share (warrant strike $4.50).
June 13, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 5.07 item 9.01

Tenax Therapeutics expands equity pool by 400k shares; CMO shifts to part-time

Stockholders approved Amendment No. 1 to 2022 Stock Incentive Plan, increasing authorized shares to 400,688.
May 14, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Tenax Therapeutics Q1 net loss widens to $3.8M; Phase 3 LEVEL study enrolling

Net loss of $3.8M vs $1.4M in Q1 2023; R&D expenses rose to $2.7M from $0.3M.
March 28, 2024, 7:59 PM ET earnings materiality 0.50 neutral item 2.02 item 9.01 ◈ Earnings Releases

Tenax Therapeutics reports FY2023 net loss $7.7M; Phase 3 LEVEL trial underway

Cash $9.8M at Dec 31, 2023; Feb 2024 public offering netted ~$8.0M.
February 23, 2024, 6:59 PM ET regulatory materiality 0.60 positive item 8.01

Tenax Therapeutics regains Nasdaq minimum float compliance; deficiency closed

Received Nasdaq notice on Feb 22, 2024 confirming over 500,000 publicly held shares.
February 20, 2024, 6:59 PM ET other material materiality 0.70 positive item 1.01 item 9.01 ◈ Material Agreements

Tenax Therapeutics expands levosimendan license to worldwide rights from Orion

Amendment expands Tenax's exclusive global rights to levosimendan for PH-HFpEF from North America to worldwide.
February 12, 2024, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements ×3

Tenax Therapeutics prices $9M public offering of common stock and warrants

1.6M shares or pre-funded warrants plus 3.2M common warrants at $5.65/unit.
February 8, 2024, 6:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Tenax Therapeutics enrolls first patient in Phase 3 LEVEL study for TNX-103 in PH-HFpEF; topline data expected H2 2025

First patient enrolled in Phase 3 LEVEL study of oral TNX-103 (levosimendan) for PH-HFpEF; 152-patient trial.
February 6, 2024, 6:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

USPTO allows patent covering levosimendan use in PH-HFpEF through 2040

USPTO Notice of Allowance for patent covering oral (TNX-103), IV, subcutaneous levosimendan, active metabolites, and drug combos for PH-HFpEF.
January 19, 2024, 6:59 PM ET other material materiality 0.75 positive item 8.01

Tenax Therapeutics regains compliance with Nasdaq minimum bid price rule

Received Nasdaq written confirmation on Jan 18, 2024, after 10 consecutive trading days (Jan 3-17) closing at $1.00 or greater.
January 12, 2024, 6:59 PM ET regulatory materiality 0.75 negative item 3.01 item 5.02 item 9.01 ◈ executive_change ×2◈ Listing & Compliance Notices

Tenax Therapeutics receives Nasdaq delisting notice; appoints interim CFO Lawrence Hoffman

Nasdaq notified Tenax on Jan 11, 2024 that it fails minimum 500,000 publicly held shares after 1-for-80 reverse split.
January 5, 2024, 6:59 PM ET other materiality 0.50 neutral item 3.03 item 5.03 item 8.01 item 9.01 ◈ Governance Changes

Tenax Therapeutics announces 1-for-80 reverse stock split effective Jan 2, 2024

Reverse split at 1:80 ratio effective 5:00 pm ET on Jan 2, 2024; trading on Nasdaq split-adjusted Jan 3 under TENX.
December 1, 2023, 6:59 PM ET other material materiality 0.60 neutral item 5.07 ◈ Shareholder Votes ×2

Tenax Therapeutics shareholders approve reverse stock split authorization

Reverse split ratio range 1:10 to 1:80, exact ratio set by board; authorized until Nov 30, 2024.
November 13, 2023, 6:59 PM ET regulatory materiality 0.85 positive item 8.01 item 9.01

FDA clears IND for Tenax's TNX-103 (oral levosimendan) for PH-HFpEF; Phase 3 LEVEL study to start Q4 2023

FDA cleared IND for TNX-103 (oral levosimendan) to treat PH-HFpEF, enabling Phase 3 LEVEL study in Q4 2023.
September 29, 2023, 7:59 PM ET regulatory materiality 0.50 neutral item 3.01 ◈ Listing & Compliance Notices

Tenax Therapeutics gets Nasdaq extension to March 25, 2024 for $1 bid price rule

Nasdaq granted extension through March 25, 2024 to regain compliance with $1.00 minimum bid price (Rule 5550(a)(2)).
August 15, 2023, 7:59 PM ET other materiality 0.30 neutral item 5.03 item 9.01 ◈ Governance Changes

Tenax Therapeutics amends bylaws to lower quorum to one-third, allow director removal without cause

Quorum for stockholder meetings reduced to one-third of shares entitled to vote from previous higher threshold.
July 19, 2023, 7:59 PM ET regulatory materiality 0.70 positive item 8.01 item 9.01

Tenax Therapeutics receives U.S. patent for oral levosimendan (TNX-103) in PH-HFpEF, expiring 2040

USPTO granted Patent No. 11,701,355 for oral levosimendan (TNX-103) to treat PH-HFpEF, with exclusivity through December 2040.
June 13, 2023, 7:59 PM ET other material materiality 0.50 negative

Tenax shareholders reject reverse stock split and stock plan amendment; directors elected

All seven director nominees elected: June Almenoff, Michael Davidson, Declan Doogan, Christopher Giordano, Robyn Hunter, Gerald Proehl, Stuart Rich.
May 31, 2023, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Tenax Therapeutics receives USPTO Notice of Allowance for oral levosimendan patent in PH-HFpEF

Patent covers oral levosimendan (TNX-103) for PH-HFpEF; term through Dec 2040, possible extension beyond.
April 13, 2023, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Tenax prioritizes oral levosimendan Phase 3 for PH-HFpEF in 2023

Company to initiate Phase 3 trial of TNX-103 (oral levosimendan) for PH-HFpEF in 2023.
March 30, 2023, 7:59 PM ET regulatory materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices

Tenax Therapeutics receives Nasdaq bid price deficiency notice; 180 days to regain compliance

Nasdaq notified Tenax on March 29, 2023 that bid price closed below $1.00 for 30 consecutive business days.
March 22, 2023, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Tenax Therapeutics receives US patent for IV levosimendan in PH-HFpEF, expiring Dec 2040

U.S. Patent No. 11,607,412 covers IV levosimendan for pulmonary hypertension with HFpEF.
February 10, 2023, 6:59 PM ET other material materiality 0.35 neutral item 1.02 item 9.01 ◈ Material Agreements

Tenax Therapeutics terminates HQ lease with $169,867 payment; no further obligations

Lease termination with CCP Concourse, LLC, effective Feb 8, 2023.
February 7, 2023, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements ×2

Tenax Therapeutics raises ~$15.6M in public offering of common stock and warrants

Priced 8,666,666 shares (or pre-funded warrants) plus 17,333,332 warrants at $1.80/unit.
February 1, 2023, 6:59 PM ET regulatory materiality 0.70 positive item 8.01 item 9.01

Tenax Therapeutics granted US patent covering IV levosimendan for PH-HFpEF until 2040

USPTO Notice of Allowance for patent covering IV levosimendan in PH-HFpEF; patent expected to last until 2040.
January 20, 2023, 6:59 PM ET regulatory materiality 0.25 positive item 8.01

Tenax regains compliance with Nasdaq minimum bid price rule

Nasdaq confirmed compliance on Jan 20, 2023 after stock closed at $1.00+ for ten consecutive trading days.
January 4, 2023, 6:59 PM ET other material materiality 0.50 negative item 3.03 item 5.03 item 8.01 item 9.01 ◈ Governance Changes

Tenax Therapeutics effects 1-for-20 reverse stock split to meet Nasdaq minimum bid price

Reverse stock split at 1-for-20 ratio effective 5:00 p.m. ET on January 4, 2023.
October 11, 2022, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Tenax Therapeutics announces positive oral levosimendan data in PH-HFpEF patients at HFSA meeting

18 PH-HFpEF patients transitioned from IV to oral levosimendan with no serious adverse events reported.